Latest From LG Group
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
LG's decision to merge its biopharma affiliate LG Life Sciences with the group's main cash cow, LG Chem, signals a focus on "red biotech" and a desire to keep up with other major South Korean conglomerates such as Samsung that are building their biopharma businesses. LG plans to sharply hike sector R&D and capital investments to position the combined operation as a future growth engine.
Pfizer’s Albert Bourla and Hiroshi Matsumori on Established Brands In Japan: An Interview With PharmAsia News
Last week’s exclusive partnership with Mylan has put Pfizer in a much stronger position in Japan’s generics market. The question remains whether it can navigate Japan’s unique Gx challenges.
One way for Pharma to bolster its lagging growth would be to capture some of the value of the compounds it has shelved during development. Start-ups have created technology platforms and systems biology approaches and are in place to reposition such stalled drugs in new indications, or to reformulate marketed compounds to extend the product life cycle. Nonetheless, drug firms largely remain reluctant to part even with compounds they have decided not to develop themselves. Drug makers say the issue is resources, but it is also desire. Until Big Pharma further loosens its grip on its compounds that are stalled in development, in-licensing will remain an opportunistic, case-by-case exercise, and biotechs must accept the fact that access will depend largely on advance insider knowledge of pharma firms' pipelines.
- Therapeutic Areas
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- LG Group
- Senior Management
- Bon-Moo Koo, Chmn.
- Contact Info
Phone: (82) 2 787 5114
20 Yeouido-dong, Yeongdeungpo-gu
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.